NASDAQ:CLNN - US1856342019 - Common Stock
The current stock price of CLNN is 5.95 USD. In the past month the price increased by 62.57%. In the past year, price increased by 0.34%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.11 | 376.28B | ||
AMGN | AMGEN INC | 12.84 | 150.79B | ||
GILD | GILEAD SCIENCES INC | 14.57 | 139.93B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.43 | 101.77B | ||
REGN | REGENERON PHARMACEUTICALS | 12.43 | 60.12B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
ARGX | ARGENX SE - ADR | 79.14 | 44.90B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.42 | 37.89B | ||
INSM | INSMED INC | N/A | 30.13B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.88B | ||
NTRA | NATERA INC | N/A | 22.86B | ||
BIIB | BIOGEN INC | 8.74 | 20.52B |
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah and currently employs 75 full-time employees. The company went IPO on 2018-08-27. The company specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
CLENE INC
6550 South Millrock Drive, Suite G50
Salt Lake City UTAH 84121 US
CEO: Robert Etherington
Employees: 76
Phone: 18016769695
The current stock price of CLNN is 5.95 USD. The price increased by 6.44% in the last trading session.
The exchange symbol of CLENE INC is CLNN and it is listed on the Nasdaq exchange.
CLNN stock is listed on the Nasdaq exchange.
12 analysts have analysed CLNN and the average price target is 31.33 USD. This implies a price increase of 426.53% is expected in the next year compared to the current price of 5.95. Check the CLENE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CLENE INC (CLNN) has a market capitalization of 59.44M USD. This makes CLNN a Micro Cap stock.
CLENE INC (CLNN) currently has 76 employees.
CLENE INC (CLNN) has a support level at 5.79. Check the full technical report for a detailed analysis of CLNN support and resistance levels.
The Revenue of CLENE INC (CLNN) is expected to decline by -47.45% in the next year. Check the estimates tab for more information on the CLNN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CLNN does not pay a dividend.
CLENE INC (CLNN) will report earnings on 2025-11-11, before the market open.
CLENE INC (CLNN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.95).
The outstanding short interest for CLENE INC (CLNN) is 3.08% of its float. Check the ownership tab for more information on the CLNN short interest.
ChartMill assigns a technical rating of 8 / 10 to CLNN. When comparing the yearly performance of all stocks, CLNN is one of the better performing stocks in the market, outperforming 78.93% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to CLNN. CLNN may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CLNN reported a non-GAAP Earnings per Share(EPS) of -3.95. The EPS increased by 11.43% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -134.26% | ||
ROE | N/A | ||
Debt/Equity | N/A |
12 analysts have analysed CLNN and the average price target is 31.33 USD. This implies a price increase of 426.53% is expected in the next year compared to the current price of 5.95.
For the next year, analysts expect an EPS growth of 65.48% and a revenue growth -47.45% for CLNN